ASH 2012: Dr. John Byrd Part 3 Accrual Issues in Clinical Trials, Transplant, CAR-T, the Rare Relapses, and Biological Combination
In this segment we are getting into some of the gritty details of treatment with ibrutinib. For the cognoscenti, this may add to your knowledge base. For those new to the ibrutinib story, I suggest you review my early ASH 2012 interviews with Dr. Pagel and the first two parts to this interview in my earlier posts.
To my non-CLL friends, I guarantee that soon I will share some amazing craic, photos, and video from Ireland. but right now, I am just having way too good a time to devote much attention to the internet.